Yorkville Advisors Global LP Purchases Shares of 75,000 Alignment Healthcare, Inc. $ALHC

Yorkville Advisors Global LP purchased a new position in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 75,000 shares of the company’s stock, valued at approximately $1,309,000. Alignment Healthcare makes up about 0.3% of Yorkville Advisors Global LP’s portfolio, making the stock its 12th biggest holding.

Other hedge funds have also recently made changes to their positions in the company. Royal Bank of Canada grew its holdings in shares of Alignment Healthcare by 92.6% during the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after purchasing an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Alignment Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock valued at $1,109,000 after buying an additional 2,594 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Alignment Healthcare by 79.1% during the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock valued at $18,112,000 after buying an additional 429,703 shares during the last quarter. Woodline Partners LP bought a new position in shares of Alignment Healthcare during the first quarter valued at about $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after buying an additional 44,452 shares during the period. 86.19% of the stock is currently owned by institutional investors.

Alignment Healthcare Trading Up 2.3%

NASDAQ:ALHC opened at $17.92 on Wednesday. The company has a 50-day moving average price of $20.62 and a 200-day moving average price of $18.79. The stock has a market cap of $3.66 billion, a price-to-earnings ratio of -1,790.21, a P/E/G ratio of 2.56 and a beta of 1.18. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the company earned ($0.16) earnings per share. Alignment Healthcare’s quarterly revenue was up 44.4% on a year-over-year basis. Equities analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ALHC shares. Robert W. Baird set a $28.00 target price on Alignment Healthcare in a research note on Friday, January 30th. UBS Group lifted their price target on Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 14th. Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. increased their price objective on Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, TD Cowen raised their target price on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alignment Healthcare presently has an average rating of “Moderate Buy” and an average target price of $24.56.

Insiders Place Their Bets

In other news, CEO John E. Kao sold 605,648 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $11,349,843.52. Following the completion of the transaction, the chief executive officer owned 2,234,294 shares of the company’s stock, valued at approximately $41,870,669.56. This represents a 21.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert L. Scavo sold 69,541 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $18.74, for a total value of $1,303,198.34. Following the completion of the transaction, the insider owned 503,014 shares of the company’s stock, valued at approximately $9,426,482.36. The trade was a 12.15% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 2,096,821 shares of company stock worth $40,774,893. Company insiders own 6.60% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.